Home |  Contact Us | Site Map

Investor Relations

Welcome! Whether you are a potential investor in BioCryst Pharmaceuticals or you are already a shareholder, our investor center is the primary source of information about the company. Just choose a topic, or if you have a question, e-mail us.

Recent Releases

Dec 18, 2014
BioCryst Initiates OPuS-2: A Clinical Trial of BCX4161 in Patients With Hereditary Angioedema

Dec 15, 2014
BioCryst Announces Initiation of a Phase 1 Clinical Trial of BCX4430 for the Treatment of Hemorrhagic Fever Viruses

View all releases »

Investor Relations

Rob Bennett, Vice President Investor Relations & Operations
919.859.7910
investorrelations@biocryst.com

Proxy Online

For more information click here.

Stockholder Services

Questions about stock transfers and lost certificates should be directed to the transfer agent:
American Stock Transfer & Trust Company
59 Maiden Lane
New York, NY 10038
1-800-937-5449 (toll free in US and Canada)
1-718-921-8200 (callers outside the US and Canada)

Stock Information
NASDAQ : BCRX
$11.16   + 0.08
Dec 19, 2014
4:00 PM ET
Quotes delayed at least 20 minutes. Information provided by eSignal.